Marker Therapeutics Inc (MRKR)

[Inoviorulez]

Well the AML study still has to go through its phase 2 study with more patients, I already know that's Marker's lead indication. But the bigger market opportunity will be solid tumors. Solid tumors is a $100 billion market opportunity. AML is roughly about a $1.5 billion to $2 billion opportunity. Which is greater to you?

I will concede though that I believe MRKR holds a future to be bought out for its MultiTAA because it can be used as an adjuvant to all treatments. Plus it has shown good results in many blood cancers. So there's that too.